Scientific advances in drug development are increasingly informed by active engagement with the growing research-focused patient population. Increasing levels of patient engagement, alongside an evolving understanding of how to learn from and validate external perspectives, are driving an innovative research
and development (R&D) ecosystem. Pfizer has been a leader in engagement with patients and patient organizations for over a decade. We are continuing to build these meaningful relationships and to expand the involvement of patients, patient organizations, and the general public in all stages of the drug discovery
and development process. Patient engagement offers new opportunities as different types of partnerships begin to develop within the evolving R&D ecosystem.